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individual born in 2005 returns a lifetime positive NPV to the
government of £160,069 with a break-even point (ie. where the
NPV becomes positive) at age 31. A child with similar charac-
teristics, but conceived using IVF, has a lifetime NPV of
£144,000 with a break-even point at age 33. Sensitivity analysis
indicated that these results are sensitive to assumptions about the
working age interval, inﬂation rate, discount rate, and increasing
age related health costs. CONCLUSION: Despite modelling limi-
tations, we conclude that under reasonable assumptions IVF
costs are relatively insigniﬁcant vis-à-vis other costs and beneﬁts
to government. While the model does not forecast the full eco-
nomic beneﬁts associated with investment in IVF, it does dem-
onstrate the potential long-term ﬁnancial returns of improved
access to IVF services.
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OBJECTIVES: To determine whether the protease inhibitor (PI)
darunavir boosted with low dose ritonavir (DRV/r) is cost-
effective, compared to currently available PIs, as part of highly
active anti-retroviral therapies (HAART), in highly pre-treated
HIV-1-infected adults who failed >1 PI-containing regimen in
European healthcare settings. This analysis included Belgium,
Italy and Sweden and focused on the payer perspective.
METHODS: A Markov model was adapted which contains 6
health states deﬁned by CD4+ T-cell-count range (<50, 51–100,
101–200, 201–350, 351–500 and >500 cells/mm3) and a state
“death” (Mauskopf et al, 2006). Clinical trial (POWER1&2)
data were used to model the composition of HAART regimens,
patient characteristics and transition probabilities during DRV/r
or comparator PI(/r) treatment, both combined with optimised
background regimen (OBR). After treatment failure, patients
were assumed to switch to tipranavir/r-containing regimens
((TPV/r)+OBR). Transition probabilities during TPV/r treatment
were obtained from published clinical trials. Utility values and
HIV-related mortality were obtained from published literature.
Published relative risks of non-HIV mortality in HIV patients
were applied to country-speciﬁc all-cause mortality statistics.
Non-HAART-related costs in each model state were derived from
observational studies in each country. Costs and effects were
discounted according to local guidelines. The quality-adjusted
lifetime incremental cost-effectiveness ratio (ICER) was calcu-
lated for the base-case. Univariate and probabilistic sensitivity
analyses were applied. RESULTS: For Sweden, Italy and Belgium
respectively, quality-adjusted life year (QALY) gains of 1.142,
1.171 and 1.397 were predicted for patients treated with DRV/r
in the base-case analysis. The base-case ICER for DRV/r was
12,211€/QALY, 16,668€/QALY and 12,584€/QALY respectively.
The DRV/r ICER remained consistently below the often quoted
threshold of 30,000€/QALY throughout extensive sensitivity
analyses. The probability of an ICER below 30,000€/QALY was
above 92% in all countries. CONCLUSION: DRV/r is predicted
to be cost-effective versus currently available PIs in highly pre-
treated HIV-1-infected adults in different European health care
settings.
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OBJECTIVES: To assess the cost-effectiveness of Intrathecal
Baclofen Therapy (ITB) versus current therapies in low level
disabled spasticity. METHODS: Two simulation models have
been constructed to assess the effectiveness, cost and cost-
effectiveness of various treatment sequences based on current
medical practices established by an international expert panel.
The ﬁrst model simulates current therapies using various
sequences of physical treatment only, oral treatments, focal spas-
ticity treatments, neuro-surgery and nursing. The second model
simulates strategies starting with ITB as the ﬁrst line treatment,
then various sequences of 2d, 3rd or 4th lines treatments includ-
ing ITB dose adjustment, explantation, oral treatments, focal
spasticity treatments, neurosurgery or nursing. The model used a
simulation decision framework and a 2-year time horizon over
four 6 months intervals. A successful treatment has been deﬁned
as a patient or caregiver satisfaction + change of 1 point in the
Ashworth score. Direct medical costs have been collected in the
frame of the French health care system. Effectiveness and cost
parameters have been included in the model according to speciﬁc
distribution shapes in order to take into account medical prac-
tices variability. Probabilistic sensitivity analyses were conducted
using 5000 Monte-Carlo simulations taking into account speciﬁc
distribution shapes for each cost and effectiveness parameters.
RESULTS: ITB as ﬁrst line strategy is the dominant strategy over
2 years, providing greater treatment success rate (78.7% versus
59.3%, p < 0.001), lower costs (59,391 Euros versus 88,272
Euros, p < 0.001) and lower cost-effectiveness (75,204 Euros/
success versus 148,822 Euros/success, p < 0.001) than current
strategies. CONCLUSION: This robust cost-effectiveness mod-
eling is the ﬁrst study assessing the cost-effectiveness of various
treatment sequences in disabled spasticity according to current
medical practices. This study establishes that introducing ITB as
the ﬁrst line therapy is a dominant strategy (more effective and
less costly) over a time period of 2 years.
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OBJECTIVES: To estimate the cost-effectiveness of a new treat-
ment (natalizumab) for multiple sclerosis (MS) compared to
current standard therapy with disease-modifying drugs (DMDs)
in Sweden. METHODS: A Markov model was constructed to
illustrate disease progression based on functional disability
(EDSS). Disease progression while on treatment with natali-
zumab was based on a two-year placebo-controlled clinical trial
in 942 patients (AFFIRM). Progression while on treatment with
current DMDs was estimated from a matched sample of 512
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patients in the Swedish MS registry for the Stockholm County.
Patients withdrawing from treatment in both arms were assumed
to follow the disease course of 824 patients with relapsing-
remitting disease at onset in the natural history cohort in
Ontario, Canada. Costs and utilities by level of disease severity
are based on a recent observational study in 1339 Swedish
patients. All data sets were available at patient-level. Main re-
sults are presented for the societal perspective, over a 20-year
time frame, in 2005 Euro (1€ = 9.25SEK) discounted at 3%.
RESULTS: In the base case, treatment with natalizumab was less
expensive and more effective than treatment with current DMDs
in Sweden, i.e. it dominated standard therapy. When only health
care costs were considered, the cost per QALY gained with
natalizumab was €38,145. Health effects are sensitive only to the
time horizon of the analysis, and assumptions about effective-
ness of natalizumab beyond the trial. CONCLUSION: This
cost-effectiveness analysis used registry data, cohort and obser-
vational studies to extrapolate the efﬁcacy ﬁndings of natali-
zumab from the AFFIRM clinical trial to measure effectiveness
in clinical practice. The analysis results suggest that for the
population considered, natalizumab provides an additional
health beneﬁt at a similar cost to current DMDs from a societal
perspective.
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OBJECTIVES: Markov modeling has been widely used to
assess the cost-effectiveness of disease modifying drugs (DMDs)
in patients with relapsing form of multiple sclerosis (RFMS). Its
limitations, along with variations in disease progression, often
lead to unrealistic clinical assumptions and oversimpliﬁcation
of the course of RFMS. This study assessed the reliability of
modeling clinical outcomes for patients receiving interferon-
beta-1a (IFNb1a) subcutaneously (SC) versus intramuscularly
(IM) using discrete event simulation (DES). METHODS: The
model creates a cohort of individual patients by reading in
actual patient proﬁles and “cloning” them-one receives IFNb1a
SC, and the other IM. Patients may suffer relapses, develop new
T2 lesions, experience adverse events, stop treatment, progress
to secondary progressive MS or die. Time for each event is
sampled from failure time distributions speciﬁed by the indi-
vidual’s risk proﬁle. When a relapse occurs, an actual relapse
proﬁle comprising severity and recovery status is assigned and
processed accordingly. Model inputs were mostly derived from
the EVidence of Interferon Dose-response European North
American Comparative Efﬁcacy (EVIDENCE) trial with a few
from published literature. Results based on 100 replications of
10,000 patient pairs were validated against the trial results.
RESULTS: Predictions at 64 weeks, the mean follow-up of the
EVIDENCE trial, were similar to the trial RESULTS: Fifty-four
percent vs. 56% (model vs. trial) of SC and 45% vs. 48% of
IM users remained relapse-free and the annual relapse rate was
0.51 vs. 0.54 with SC and 0.66 vs. 0.65 with IM use. Of
relapses, 57% required no treatment, 36% an outpatient visit,
and 7% a hospital stay, almost identical to the trial results with
57%, 36%, and 8%, respectively. CONCLUSION: Use of DES
permits realistic modeling of DMDs in RFMS, use of actual
patient-level data, and avoided unrealistic assumptions, while
closely predicting the clinical outcomes with efﬁciency, ﬂexibil-
ity and transparency.
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OBJECTIVES: To assess the cost-effectiveness of the Versatis
lidocaine 5% medicated plaster relative to 300 and 600 mg/day
pregabalin in the treatment of post-herpetic neuralgia (PHN)
from the perspective of the Scottish National Health Service.
METHODS: The costs and beneﬁts of the three treatments were
assessed over a six-month time horizon using a Markov model.
The model structure allowed for differences in costs, utilities and
transition probabilities between the initial 30-day run-in period
and maintenance therapy and took account of add-in medication
and drugs received by patients discontinuing therapy. Transition
probabilities were based on clinical trials and Delphi panel
estimates. Resource use and add-in/switch medications were
obtained from 2 Delphi panels; cost data were from ofﬁcial price
tariffs. Published utilities were adjusted for age and were
supplemented/validated by a Delphi panel. Lidocaine-treated
patients were assumed to receive 1.03 plasters/day based on US
prescribing data. RESULTS: The average patient receiving the
lidocaine plaster accrued 0.292 quality-adjusted life-years
(QALYs) over six months—0.067 more than 300 mg pregabalin
and 0.061 more than 600 mg pregabalin. The total treatment
cost for patients receiving the lidocaine plaster (£681/patient)
was very similar to that for 300 mg pregabalin (£636/patient)
and 600 mg pregabalin (£655/patient). The lidocaine plaster cost
£674/QALY (95% conﬁdence interval [95% CI]: dominant,
£4,780) relative to 300 mg/day pregabalin and £434/QALY
(95% CI: dominant, £5,009) relative to 600 mg/day pregabalin.
Probabilistic sensitivity analysis demonstrated that we can be
99.9% conﬁdent that the lidocaine plaster is cost-effective rela-
tive to 300 mg pregabalin and 99.8% conﬁdent that it is cost-
effective relative to 600 mg pregabalin at a £20,000/QALY
threshold. The lidocaine plaster cost £27 per additional month
with sufﬁcient pain relief and no intolerable side-effects relative
to 300 mg pregabalin and £18/month relative to 600 mg pre-
gabalin. CONCLUSION: The Versatis lidocaine 5% medicated
plaster is a highly cost-effective alternative to pregabalin for the
treatment of PHN in Scotland.
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OBJECTIVES: The currently available formulations budesonide/
formoterol (BUD/FORM, Symbicort) and salmeterol/ﬂuticasone
(SAL/FLU, Seretide) have been shown to be effective in the treat-
ment of asthma. This study compared outcomes with BUD/
FORM and SAL/FLU in real-life practice. METHODS: Cohorts
of asthma patients initiated on BUD/FORM or SAL/FLU
between 2001 and 2006 were identiﬁed from IMS Disease Ana-
lyzer, a longitudinal UK database of physician records. Patients
were followed 12 months before and after treatment initiation
(TI). Treatment success was deﬁned as no oral corticosteroid
A240 Abstracts
